Amarin vs Lifevantage
AMRN and LFVN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMRN and LFVN compare
Amarin is the larger company, worth 81 times as much as Lifevantage ($5.0B against $62.3M).
Amarin grew revenue faster over the last twelve months (−22.3% versus −24.8% for Lifevantage).
Lifevantage keeps more of each dollar of sales as profit, with a net margin of 1.6% compared with −10.9% at Amarin.
Lifevantage pays a dividend yielding 3.8%; Amarin does not pay one.
Lifevantage scores higher on the StockData Score (16 against 10 for Amarin), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMRN | LFVN |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | $62.3M |
| Share price | $11.38 | $4.97 |
| Change, 1 year | −29.8% | −25.2% |
| Change, 5 years | −85.4% | −32.7% |
| Beta (5Y) | 1.54 | 0.38 |
| Employees | 80 | 223 |
| StockData Score | ||
| Total score | 10 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 1 | 1 |
| Performance score | 3 | 3 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 23.7× |
| P/S | 28.6× | 0.4× (better) |
| P/B | 11.3× | 1.9× (better) |
| EV/EBITDA | – | 7.4× |
| P/FCF | – | 7.2× |
| PEG | – | 0.91 |
| FCF yield | – | 14.0% |
| Fair value | $7.00 | $6.48 |
| Margin of safety | −62.5% | 23.3% (better) |
| Growth | ||
| Revenue growth (TTM) | −22.3% (better) | −24.8% |
| Revenue growth, 5Y average | −19.0% | −3.7% (better) |
| Net income growth (TTM) | – | −73.1% |
| EPS growth (TTM) | – | −72.7% |
| EPS growth, 5Y average | – | −15.0% |
| Profitability | ||
| Gross margin | 40.9% | 76.5% (better) |
| Operating margin | −18.2% | 2.1% (better) |
| Net margin | −10.9% | 1.6% (better) |
| FCF margin | – | 5.1% |
| Return on equity | −4.2% | 8.2% (better) |
| Return on invested capital | −17.3% | 14.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.50 (better) | 1.91 |
| Altman Z-score | 13.05 (better) | 2.42 |
| Piotroski F-score | 7 (better) | 6 |
| Dividends and buybacks | ||
| Dividend yield | – | 3.8% |
| Payout ratio | – | 88.2% |
| Years of dividend growth | – | 1 |
| Buyback yield | – | 2.4% |
| Shareholder yield | 0.00% | 6.2% (better) |
| Ownership | ||
| Held by institutions | 1.0% | 47.2% |
| Held by insiders | 7.0% | 27.8% |
| Insider net buying, 12 months | – | $54.8K |
| Short interest, % of float | – | 10.0% |
Go deeper
- AMRN stock overview
- AMRN income statement
- AMRN valuation and score
- LFVN stock overview
- LFVN income statement
- LFVN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.